A Phase 2, Multicenter Study of Tesevatinib Monotherapy in Patients with Recurrent Glioblastoma
A study for patients with Glioblastoma using study drug Tesevatinib monotherapy
Sponsor: Kadmon Corporation, LLC
Enrolling: Male and Female Patients
IRB Number: AAAR1035
U.S. Govt. ID: NCT02844439
Contact: Andrew Lassman: 212-342-0871 / abl7@cumc.columbia.edu
Additional Study Information: The reason for this study is to find out if the experimental study drug, tesevatinib, is effective as a possible treatment for recurrent glioblastoma. Certain genetic information about your tumor will also be collected, by drawing blood, to help better understand why tesevatinib did or did not work in treating your recurrent glioblastoma. Although tesevatinib has been given to people with other cancers, to people with polycystic kidney disease, and to healthy volunteers, this is the first study in which it has been given to research subjects with recurrent glioblastoma.
This study is closed
Andrew Lassman, MD
Do You Qualify?
Are you at least 18 years of age? Yes No
Have you been diagnosed with glioblastoma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Andrew Lassman